Clinical trial
Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal…
NCT00237133 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00237133 |
|---|---|
| Title | Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women |
| Official title | PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR) |
| Acronym | PREDICT |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Locally Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Letrozole |
| Enrollment | 112 |
| Start date | Mar 1, 2003 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 21, 2009 |
| First posted | Oct 12, 2005 |
| Last update posted | Feb 24, 2017 |
| Countries | Brazil |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: